Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant

Transplantation

Volumn 61, Issue 5, 1996, Pages 738-745

  Henslee Downey, P Jean ^a,b,c   Parrish, Rudolph S ^a   Macdonald, John S ^b,d   Romond, Edward H ^b   Marciniack, Ewa ^b   Coffey, Charles ^b,e   Ciocci, Gilbert ^b,f   Thompson, John S ^b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c Division of Transplantation Medicine   (United States)

^d TEMPLE UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOFOS; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H65 RTA; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FAMILY; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOTOXINS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RABBITS; RICIN;

EID: 0029923272     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199603150-00012     Document Type: Article

References (41)

1. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511.
2. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347.
3. Krivit W, Shapiro E, Hoogerbrugge PM, et al. State-of-the-art review: bone marrow transplantation treatment for storage disease. Bone Marrow Transplant 1992; 10 (suppl 1): 87.
4. Clift RA, Hansen JA, Thomas ED, et al. Marrow transplantation from donors other than HLA-identical siblings. Transplantation 1979; 28 (3): 235.
5. Trigg ME, Billing R, Sondel PM, et al. Mismatched bone marrow transplantation in children with hematologic malignancy using T-lymphocyte depleted bone marrow. J Biol Response Mod 1985; 4: 602.
6. Henslee PJ. Choosing an alternative donor among available family members. Am J Pediatr Hematol Oncol 1993; 15(2): 150.
7. Gingrich RD, Howe CWS, Gocken NE, et al. The use of partially matched unrelated donors in clinical bone marrow transplantation. Transplantation 1985; 39: 526.
8. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the national donor program. N Engl J Med 1993; 328: 593.
9. Trigg ME. Bone marrow transplantation using alternative donors: mismatched related donors or closely matched unrelated donors. Am J Pediatr Hematol Oncol 1993; 15(2): 141.
10. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197.
11. Davies SM, Ramsay NKC, Haake RJ, et al. Comparison of engraftment in recipients of matched sibling or unrelated donor marrow allografts. Bone Marrow Transplant 1994; 13(1): 51.
12. Beatty PG, Cliff RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA identical siblings. N Engl J Med 1985; 313: 765.
13. Beatty PG, Hansen JA, Longton GM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443.
14. Marks DL, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207.
15. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520.
16. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporin as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325.
17. Ramsay NKC, Kersey JH, Robinson LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392.
18. Forman SJ, Blume KG, Krance RA, et al. A prospective randomized study of acute graft-versus-host disease in 107 patients with leukemia: methotrexate/prednisone v. cyclosporine-A/ prednisone. Transplant Proc 1987; 19(1): 2605.
19. Herve P, Bordigoni P, Cahn JY, et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation. Transplant Proc 1991; 23(1): 1692.
20. O'Reilly RJ. T cell depletion and allogeneic bone marrow transplantation. Semin Hematol 1992; 29 (suppl 1): 20.
21. Henslee PJ, Thompson JS, Romond EH, et al. T-cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect. Transplant Proc 1987; 19(1): 2701.
22. Kernan N, Collins NH, Juliano L, et al. Clonable T-lymphocytes in T-cell-depleted bone marrow transplants correlate with development of graft-versus-host disease. Blood 1986; 68: 770.
23. Cullis JO, Szydlo RM, Cross NC, et al. Matched unrelated donor bone marrow transplantation for chronic myeloid leukemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion. Bone Marrow Transplant 1993; 11 (suppl 1): 107.
24. Henslee PJ, Byers VS, Jennings CD, et al. A new approach to the prevention of graft-versus-host disease (GVHD) using Xomazyme-H65 following histo-incompatible partially T-depleted marrow grafts. Transplant Proc 1989; 21(1): 3004.
25. Kernan NA, Knowles RW, Burnes MJ, et al. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T-cell (gp67) ricin A chain immunotoxin. J Immunol 1984; 133: 137.
26. Marciniak E, Romond EH, Thompson JS, Henslee PJ. Laboratory control in predicting clinical efficacy of T-cell depletion procedures used for prevention of graft-versus-host disease: importance of limiting dilution analysis. Bone Marrow Transplant 1988; 3(6): 589.
27. McCullough J, Rogers G, Dahl R, et al. Development and operation of a program to obtain volunteer bone marrow donors unrelated to the patient. Transfusion 1986; 26: 315.
28. Hows J, Bradley BA, Gore S, et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371.
29. Sonnenberg FA, Eckman MH, Pauker SG. Bone marrow donor registries: the relation between registry size and probability of finding complete and partial matches. Blood 1989; 74: 2569.
30. Korngold R, Sprent J. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 1985; 135: 3004.
31. O'Reilly RJ. Transplantation of soybean lectin treated bone marrow in primary immunodeficiency. In: Champlin R, Gale RP, eds. Recent advances in bone marrow transplantation. New York: Liss, 1986: 483.
32. O'Reilly RS, Collins NH, Kernan N, et al. Transplantation of marrow-depleted T-cells by soybean lectin agglutination and E-rosette depletion: major histocompatibility complex-related graft resistance in leukemic transplant patients. Transplant Proc 1985; 17: 455.
33. Bozdich M, Sondel PM, Trigg ME, et al. Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pre-transplant conditioning prevents rejection. Exp Hematol 1985; 13: 1201.
34. Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015.
35. Byers VS, Henslee PJ, Kernan NA, et al. Use of an anti-pan T-lymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990; 75(7): 1426.
36. Krance R, Heslop HE, Mahmond H, et al. Anti-pan T-lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant 1993; 11: 33.
37. Weisdorf D, Fillipovich A, McGlave P, et al. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation. Bone Marrow Transplant 1993; 12(5): 531.
38. Przepiorka D, von Wolff B, Ippoliti C, et al. Anti-CD5 ricin A chain immunotoxin decreases acute graft-vs-host disease after unrelated donor marrow transplantation. Exp Hematol 1992; 20: 709.
39. Beatty PG. The immunogenetics of bone marrow transplantation. Transfus Med Rev 1994; 8(1): 45.
40. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
41. Rowlings PA, Gale RP, Horowitz MM, Bortin MM. Bone marrow transplantation in leukemia. Am J Hematol 1994; 3: 235.